SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012; 30: 2718-2724.
  • 2
    Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-2637.
  • 3
    Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005; 11: 5319-5328.
  • 4
    Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366: 520-529.
  • 5
    Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. Cancer Res. 2011; 71( 24 suppl 3): 105s-106s. Abstract 3–7.
  • 6
    Piccart-Gebhart MJ, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol. 2012; 30( suppl). Abstract 559.
  • 7
    Novartis Pharmaceuticals. Afinitor (everolimus) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf. Accessed June 26, 2012.
  • 8
    Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase. J Natl Cancer Inst. 2005; 97: 1568-1574.
  • 9
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80( suppl 8): 1588-1594.
  • 10
    Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22: 3608-3617.
  • 11
    Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007; 13: 1648-1655.
  • 12
    Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593.
  • 13
    Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010; 107: 85-91.
  • 14
    Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009; 117: 577-589.
  • 15
    Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008; 27: 32.
  • 16
    Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol. 2002; 3: 620-628.
  • 17
    Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997; 15: 974-986.
  • 18
    Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26: 1664-1670.
  • 19
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001.
  • 20
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002; 77: 371-383.
  • 21
    Maringwa JT, Quinten C, King M, et al; EORTC PROBE project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011; 19: 1753-1760.
  • 22
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16: 139-144.
  • 23
    Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007; 110: 196-202.
  • 24
    Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002; 324: 1417.
  • 25
    Rugo HS, Pritchard KI, Gnant M, et al. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: long-term efficacy and safety results of the BOLERO-2 trial [abstract]. Eur J Cancer. 2012;48(suppl 1):S116. Abstract 253.
  • 26
    Helgeson VS, Tomich PL. Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women. Psychooncology. 2005; 14: 307-317.
  • 27
    Goodwin PJ, Ennis M, Bordeleau LJ, et al. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol. 2004; 22: 4184-4192.
  • 28
    Wu Y, Amonkar MM, Sherrill BH, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011; 22: 2582-2590.
  • 29
    Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y. Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat. 2010; 123: 785-793.
  • 30
    Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011; 78: 127-137.
  • 31
    Strada MR, Palumbo R, Bernardo A, et al. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials. Clin Breast Cancer. 2012; 12: 30-39.
  • 32
    Nuzzo F, Morabito A, Gravina A, et al. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer. 2011; 11: 75.
  • 33
    Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010; 15: 944-953.
  • 34
    Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011; 29: 413-420.
  • 35
    Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012; 29: 432-438.